US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

COSCIENS Biopharma Inc

3.05

+0.22137.82%

Volume:1.98K

Turnover:5.90K

Market Cap:9.60M

PE:-0.51

High:3.06

Open:2.92

Low:2.92

Close:2.83

Loading ...

Overview Company News Filings

Cosciens Biopharma Names Anna Biehn as Chief Executive

Cosciens Biopharma appoints Biehn as CEO

COSCIENS Biopharma Inc. Appoints Global Consumer Products and Biosciences Executive, Anna Biehn as Chief Executive Officer

COSCIENS Biopharma Full Year 2024 Earnings: US$5.93 loss per share (vs US$13.64 loss in FY 2023)

Simply Wall St.

COSCIENS Biopharma Q4 EPS $(2.15) Down From $(0.85) YoY, Sales $3.30M Up From $1.20M YoY

AEterna Zentaris Q4 EPS $(2.15) Down From $(0.85) YoY, Sales $3.30M Up From $1.20M YoY

COSCIENS Biopharma Inc. Reports Fourth Quarter and Full Year 2024 Financial Results and Provides a Corporate Update

COSCIENS Biopharma Inc. Announces Receipt of Management Cease Trade Order

Cosciens Biopharma to Start Phase 2a of Inflammation Drug Candidate

MT Newswires Live

COSCIENS Biopharma Inc. Announces Successful Phase 1 Results Supporting Initiation of Phase 2a Clinical Efficacy Trial with Avenanthramides as a Potential Anti-Inflammatory Product

Press Release: Perrigo Provides Detailed Plan to Consumerize, Simplify and Scale its Unique Global Self-Care Platform at its Virtual Investor Day

Cosciens Biopharma provides update, reiterates pipeline prioritization

COSCIENS Biopharma Inc. Provides Corporate Update and Highlights Pipeline Prioritization

COSCIENS Biopharma Third Quarter 2024 Earnings: US$1.85 loss per share (vs US$3.41 loss in 3Q 2023)

Simply Wall St.

COSCIENS Biopharma Inc. Reports Third Quarter 2024 Financial Results and Provides Update on Advancements with Merger Integration Process and Ongoing Development Programs

Perrigo Reports Third Quarter 2024 Financial Results From Continuing Operations

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/CSCI/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"CSCI","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"CSCI\",,,,,undefined,":{"symbol":"CSCI","market":"US","secType":"STK","nameCN":"COSCIENS Biopharma Inc","latestPrice":3.05,"timestamp":1745265600000,"preClose":2.8287,"halted":0,"volume":1977,"delay":0,"floatShares":2842440,"shares":3146225,"eps":-5.930714,"marketStatus":"Pre-Mkt","change":0.2213,"latestTime":"04-22 04:22:28 EDT","open":2.92,"high":3.06,"low":2.92,"amount":5899.5779,"amplitude":0.049493,"askPrice":4.99,"askSize":200,"bidPrice":1.83,"bidSize":100,"shortable":3,"etf":0,"ttmEps":-5.930714,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1745328600000},"marketStatusCode":1,"adr":0,"listingDate":957931200000,"exchange":"NASDAQ","adjPreClose":3.12,"postHourTrading":{"tag":"盘后","latestPrice":3.12,"preClose":3.05,"latestTime":"16:00 EDT","volume":8,"amount":24.96,"timestamp":1745265602168},"volumeRatio":0.9068806673849051},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"CSCI\",,,,,undefined,":{"symbol":"CSCI","floatShares":2842440,"roa":"-21.13%","roe":"-89.54%","lyrEps":-5.930714,"volumeRatio":0.9068806673849051,"shares":3146225,"dividePrice":0,"high":3.06,"amplitude":0.049493,"preClose":2.8287,"low":2.92,"week52Low":1.96,"pbRate":"0.73","psRate":"1.00","week52High":11.1,"institutionHeld":0,"latestPrice":3.05,"committee":-0.333333,"eps":-5.930714,"divideRate":0,"volume":1977,"delay":0,"ttmEps":-5.930714,"open":2.92,"prevYearClose":2.77,"prevWeekClose":2.8287,"prevMonthClose":2.82,"prevQuarterClose":2.82,"fiveDayClose":2.8485,"twentyDayClose":3.2,"sixtyDayClose":2.875},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"CSCI\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2527155248","title":"Cosciens Biopharma Names Anna Biehn as Chief Executive","url":"https://stock-news.laohu8.com/highlight/detail?id=2527155248","media":"Dow Jones","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527155248?lang=en_us&edition=fundamental","pubTime":"2025-04-14 19:26","pubTimestamp":1744629960,"startTime":"0","endTime":"0","summary":"Cosciens Biopharma appointed Anna Biehn as the specialty biopharmaceutical company's next chief executive, turning to an executive with more than 25 years experience in the consumer products and biosciences industries.Biehn will take up the post May 5, succeeding Gilles Gagnon, who will remain with the Canadian company as a strategic adviser and director, Cosciens said Monday.Biehn most recently served as the chief financial officer of NuTek Natural Ingredients, a \"clean-label\" and plant-based food ingredient company. Prior to her position s CFO, Biehn was vice president of strategy and marketing. She began her career at packaged food company Conagra, where she held a number of roles including as president responsible for leading the company's international business.Gagnon last September said Cosciens' board had hired an executive recruiting firm to help identify the company's next president and CEO.Cosciens, which was created with last year's all-stock merger of Aeterna Zentaris and C","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CSCI","BK4139"],"gpt_icon":0},{"id":"2527153041","title":"Cosciens Biopharma appoints Biehn as CEO","url":"https://stock-news.laohu8.com/highlight/detail?id=2527153041","media":"TIPRANKS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527153041?lang=en_us&edition=fundamental","pubTime":"2025-04-14 19:16","pubTimestamp":1744629388,"startTime":"0","endTime":"0","summary":"COSCIENS Biopharma (CSCI)announced the appointment of Anna Biehn as Chief Executive Officer, CEO, effective May 5, 2025. Biehn is a global general ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/cosciens-biopharma-appoints-biehn-as-ceo?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/cosciens-biopharma-appoints-biehn-as-ceo?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CSCI","BK4139"],"gpt_icon":0},{"id":"2527538721","title":"COSCIENS Biopharma Inc. Appoints Global Consumer Products and Biosciences Executive, Anna Biehn as Chief Executive Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2527538721","media":"GlobeNewswire","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527538721?lang=en_us&edition=fundamental","pubTime":"2025-04-14 19:00","pubTimestamp":1744628400,"startTime":"0","endTime":"0","summary":"25+ years of experience in executive leadership roles and developing global strategic growth plans with repeatable models applicable across markets, categories and channels Current President and CEO, ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/04/14/3060787/0/en/COSCIENS-Biopharma-Inc-Appoints-Global-Consumer-Products-and-Biosciences-Executive-Anna-Biehn-as-Chief-Executive-Officer.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1429558221.USD","LU2326559502.SGD","BK4564","CSCI","LU1435385759.SGD","BK4585","BK4516","BK4588","BK4139","GACQ","BK4551","BK4187"],"gpt_icon":1},{"id":"2526027326","title":"COSCIENS Biopharma Full Year 2024 Earnings: US$5.93 loss per share (vs US$13.64 loss in FY 2023)","url":"https://stock-news.laohu8.com/highlight/detail?id=2526027326","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526027326?lang=en_us&edition=fundamental","pubTime":"2025-04-12 20:15","pubTimestamp":1744460104,"startTime":"0","endTime":"0","summary":"We've found 21 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free.TSX:CSCI Earnings and Revenue History April 12th 2025. All figures shown in the chart above are for the trailing 12 month  period. COSCIENS Biopharma shares are up 6.6% from a week ago.You still need to take note of risks, for example - COSCIENS Biopharma has   4 warning signs    we think you should know about.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/cosciens-biopharma-full-2024-earnings-121504095.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["CSCI"],"gpt_icon":0},{"id":"2526349529","title":"COSCIENS Biopharma Q4 EPS $(2.15) Down From $(0.85) YoY, Sales $3.30M Up From $1.20M YoY","url":"https://stock-news.laohu8.com/highlight/detail?id=2526349529","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526349529?lang=en_us&edition=fundamental","pubTime":"2025-04-10 05:08","pubTimestamp":1744232882,"startTime":"0","endTime":"0","summary":"COSCIENS Biopharma Q4 EPS $(2.15) Down From $(0.85) YoY, Sales $3.30M Up From $1.20M YoY","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/04/44724482/cosciens-biopharma-q4-eps-2-15-down-from-0-85-yoy-sales-3-30m-up-from-1-20m-yoy","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CSCI"],"gpt_icon":0},{"id":"2526334673","title":"AEterna Zentaris Q4 EPS $(2.15) Down From $(0.85) YoY, Sales $3.30M Up From $1.20M YoY","url":"https://stock-news.laohu8.com/highlight/detail?id=2526334673","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526334673?lang=en_us&edition=fundamental","pubTime":"2025-04-10 05:03","pubTimestamp":1744232607,"startTime":"0","endTime":"0","summary":"AEterna Zentaris (NASDAQ:CSCI) reported quarterly losses of $(2.15) per share. This is a 152.94 percent decrease over losses of $(0.85) per share from the same period last year.  The company reported $3.30 million in","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/04/44724363/aeterna-zentaris-q4-eps-2-15-down-from-0-85-yoy-sales-3-30m-up-from-1-20m-yoy","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CSCI"],"gpt_icon":0},{"id":"2526346249","title":"COSCIENS Biopharma Inc. Reports Fourth Quarter and Full Year 2024 Financial Results and Provides a Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2526346249","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526346249?lang=en_us&edition=fundamental","pubTime":"2025-04-10 05:00","pubTimestamp":1744232400,"startTime":"0","endTime":"0","summary":"Fully repositioned as a pure-play natural-based product company following strategic review and pipeline prioritization. Ongoing streamlined efficiencies and cost cutting measures taken to refine operations and development pathway forward; Company ended the quarter with US$16.4 million in cash. Revenues of US$9.6M vs US$7.1M in 2023, a 35.2% increase YOY. TORONTO, ONTARIO, April 09, 2025  -- COSCIENS Biopharma Inc.   , a Life Science company which develops and commercializes a diversified portfolio of cosmeceutical, nutraceutical and pharmaceutical products, today reported its financial and operating results for the fourth quarter and full year ended December 31, 2024 and provided a corporate update.“2024 was a transformative year for COSCIENS Biopharma. Since the completion of the merger, we have developed a strategic roadmap, established a prioritized pipeline and consolidated financials. All of these efforts align with our strategic imperatives of reducing the expected combined cash ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/cosciens-biopharma-inc-reports-fourth-210000688.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["AVA","LU1878469433.USD","BK4208","CSCI","BK4139"],"gpt_icon":0},{"id":"2524417331","title":"COSCIENS Biopharma Inc. Announces Receipt of Management Cease Trade Order","url":"https://stock-news.laohu8.com/highlight/detail?id=2524417331","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524417331?lang=en_us&edition=fundamental","pubTime":"2025-04-02 07:25","pubTimestamp":1743549900,"startTime":"0","endTime":"0","summary":"TORONTO, ONTARIO, April  01, 2025  (GLOBE NEWSWIRE) -- COSCIENS Biopharma Inc. (NASDAQ: CSCI) (TSX: CSCI) (“COSCIENS” or the “Company”), a life science company which develops and commercializes a dive","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/04/01/3053872/0/en/COSCIENS-Biopharma-Inc-Announces-Receipt-of-Management-Cease-Trade-Order.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CSCI","BK4139"],"gpt_icon":0},{"id":"2519836870","title":"Cosciens Biopharma to Start Phase 2a of Inflammation Drug Candidate","url":"https://stock-news.laohu8.com/highlight/detail?id=2519836870","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2519836870?lang=en_us&edition=fundamental","pubTime":"2025-03-13 20:20","pubTimestamp":1741868440,"startTime":"0","endTime":"0","summary":"Cosciens Biopharma  said Thursday it has started the phase 2a clinical efficacy study of its avenanthramides product, which it is developing for potential applications in managing conditions related to inflammation.In phase 2a of the study, 20 patients with mild to moderate inflammation will participate. This phase is designed to assess potential efficacy in two arms with patients receiving selected doses of 480 mg and 960 mg per day, the company said. Initial dosing is expected to occur on March 14.The Data Safety and Monitoring Board recommended initiating phase 2a after phase 1, done in November 2023, showed the favorable safety profile of the product, the company said.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["CSCI","BK4139"],"gpt_icon":0},{"id":"2519330218","title":"COSCIENS Biopharma Inc. Announces Successful Phase 1 Results Supporting Initiation of Phase 2a Clinical Efficacy Trial with Avenanthramides as a Potential Anti-Inflammatory Product","url":"https://stock-news.laohu8.com/highlight/detail?id=2519330218","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2519330218?lang=en_us&edition=fundamental","pubTime":"2025-03-13 19:55","pubTimestamp":1741866900,"startTime":"0","endTime":"0","summary":"No significant clinical adverse event observed in Phase 1clinical studyPharmacokinetic profile established and range of doses selected for Phase 2a Clinical Efficacy StudyFirst patient expected to be ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/03/13/3042108/0/en/COSCIENS-Biopharma-Inc-Announces-Successful-Phase-1-Results-Supporting-Initiation-of-Phase-2a-Clinical-Efficacy-Trial-with-Avenanthramides-as-a-Potential-Anti-Inflammatory-Product.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MHI","CSCI","BK4139"],"gpt_icon":0},{"id":"2514325813","title":"Press Release: Perrigo Provides Detailed Plan to Consumerize, Simplify and Scale its Unique Global Self-Care Platform at its Virtual Investor Day","url":"https://stock-news.laohu8.com/highlight/detail?id=2514325813","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514325813?lang=en_us&edition=fundamental","pubTime":"2025-02-28 20:15","pubTimestamp":1740744900,"startTime":"0","endTime":"0","summary":"Perrigo Provides Detailed Plan to Consumerize, Simplify and Scale its Unique Global Self-Care Platform at its Virtual Investor Day. Perrigo's unique complementary businesses enables each individually to play a specific reinforcing role, where 1) store brands and infant formula generate cash for investments into the Company's key higher margin, higher growth or 'High-Grow' brands, 2) branding and innovation capabilities that deliver brand and store brand demand generation leading to stronger customer partnerships, 3) consumer-led innovation that is scaled across brands, store brands and geographies, and 4) the Company's global supply chain scale and reach with 100-plus molecules, at 100% consumer price point coverage, serves the most consumers.The Company's plan to drive cash flow and total shareholder return is anchored behind its 'Three-S' plan -- 'Stabilizing' Consumer Self-Care Americas  store brand and infant formula businesses; 'Streamlining' the global portfolio, enterprise opera","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BK4139","CSCI","BK4232","IE00BFMHRM44.USD","PRGO","R","BK4022"],"gpt_icon":0},{"id":"2493752628","title":"Cosciens Biopharma provides update, reiterates pipeline prioritization","url":"https://stock-news.laohu8.com/highlight/detail?id=2493752628","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2493752628?lang=en_us&edition=fundamental","pubTime":"2024-12-23 20:50","pubTimestamp":1734958207,"startTime":"0","endTime":"0","summary":"COSCIENS Biopharma (CSCI)provided a corporate update and reiterated its pipeline prioritization. The company said, “Pharmaceuticals: Avenanthramide...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/cosciens-biopharma-provides-update-reiterates-pipeline-prioritization?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/cosciens-biopharma-provides-update-reiterates-pipeline-prioritization?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","CSCI"],"gpt_icon":0},{"id":"2493754456","title":"COSCIENS Biopharma Inc. Provides Corporate Update and Highlights Pipeline Prioritization","url":"https://stock-news.laohu8.com/highlight/detail?id=2493754456","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2493754456?lang=en_us&edition=fundamental","pubTime":"2024-12-23 20:45","pubTimestamp":1734957900,"startTime":"0","endTime":"0","summary":"Company leveraging core competencies to develop and commercializenatural-based products to improve health and wellness  Streamlined efficiencies and cost cutting measures taken to refine operations an","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/12/23/3001176/0/en/COSCIENS-Biopharma-Inc-Provides-Corporate-Update-and-Highlights-Pipeline-Prioritization.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CSCI","BK4139"],"gpt_icon":0},{"id":"2483328588","title":"COSCIENS Biopharma Third Quarter 2024 Earnings: US$1.85 loss per share (vs US$3.41 loss in 3Q 2023)","url":"https://stock-news.laohu8.com/highlight/detail?id=2483328588","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483328588?lang=en_us&edition=fundamental","pubTime":"2024-11-15 18:10","pubTimestamp":1731665428,"startTime":"0","endTime":"0","summary":"TSX:CSCI Earnings and Revenue History November 15th 2024. All figures shown in the chart above are for the trailing 12 month  period. COSCIENS Biopharma shares are down 4.4% from a week ago.Be aware that  COSCIENS Biopharma is showing  6 warning signs in our investment analysis and 3 of those are potentially serious...","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/5Vpve0Pc2F3m_L3fs2p_dQ--~B/aD02MzY7dz05NDU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/78a8c60a6283aea0450523395306d38c","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/5Vpve0Pc2F3m_L3fs2p_dQ--~B/aD02MzY7dz05NDU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/78a8c60a6283aea0450523395306d38c"],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/cosciens-biopharma-third-quarter-2024-101028142.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["CSCI"],"gpt_icon":0},{"id":"2482069397","title":"COSCIENS Biopharma Inc. Reports Third Quarter 2024 Financial Results and Provides Update on Advancements with Merger Integration Process and Ongoing Development Programs","url":"https://stock-news.laohu8.com/highlight/detail?id=2482069397","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2482069397?lang=en_us&edition=fundamental","pubTime":"2024-11-12 20:30","pubTimestamp":1731414600,"startTime":"0","endTime":"0","summary":"Continued execution on merger integration with Ceapro Inc. and advancements across business. Company ended the quarter with US$20.0 million in cash. “We have conducted a thorough evaluation and prioritization of our combined pipeline of products and programs. This evaluation focused on prioritizing programs and products in the nutraceutical and cosmeceutical space and critically assessing the required investment and timelines for our pharmaceutical projects to reach key value inflection points. We are pleased with the continued progress in our Phase 1/2a clinical trial of our Avenanthramide product being developed as a potential anti-inflammatory. We remain on track to complete enrollment of the Phase 1 component by the end of 2024 and expect to complete enrollment in the Phase 2a component by Q3 2025. In contrast, the projected timelines and costs to reach the next value inflection point in the pre-clinical auto-immune modifying disease  platform and Delayed Clearance Parathyroid Horm","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/2NrSufQlBJ8cvPnAjnekyg--~B/aD0xNzg7dz00NjY7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/02ecd2d0ba6903975ae246a36fd6e2b1","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/2NrSufQlBJ8cvPnAjnekyg--~B/aD0xNzg7dz00NjY7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/02ecd2d0ba6903975ae246a36fd6e2b1"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/cosciens-biopharma-inc-reports-third-123000570.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","CSCI"],"gpt_icon":0},{"id":"2481267224","title":"Perrigo Reports Third Quarter 2024 Financial Results From Continuing Operations","url":"https://stock-news.laohu8.com/highlight/detail?id=2481267224","media":"PR Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481267224?lang=en_us&edition=fundamental","pubTime":"2024-11-06 19:30","pubTimestamp":1730892600,"startTime":"0","endTime":"0","summary":"Company Delivered Solid Third Quarter Financial Results, Including Meaningful Operating Income Growth and Margin Expansion. Infant Formula Business Recovery Making Significant Progress, Including Perrigo Produced and Store Brand Infant Formula Market Share Gains1; Third Quarter 2024 Infant formula Net Sales Growth of +3% Compared to the Prior Year Quarter, +58% Sequentially. Net sales of $1.1 billion declined 3.2% versus the prior year quarter. Organic2 net sales decreased 2.4%, due primarily to -2.8 percentage points from previously disclosed lost distribution of lower margin products in U.S. Store Brand. This expected impact was partially offset by organic growth of +0.4 percentage points across the rest of the business.Consumer Self-Care Americas  net sales decreased 4.6% compared to the prior year quarter, due primarily to -4.4 percentage points from previously disclosed lost distribution of lower margin products in U.S. Store Brand. Infant formula net sales grew +3% compared to th","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/LSE9dO0gJa1PZnRN5I4Lkg--~B/aD0xNjM7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/58a55f8503cfc72bd230dcf598941232","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/LSE9dO0gJa1PZnRN5I4Lkg--~B/aD0xNjM7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/58a55f8503cfc72bd230dcf598941232"],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/perrigo-reports-third-quarter-2024-113000485.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/perrigo-reports-third-quarter-2024-113000485.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["PRGO","IE00BFMHRM44.USD","CSCI","BK4139","BK4007"],"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":16,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/CSCI\",params:#limit:5,,,undefined,":[{"market":"US","date":"2024-05-14","symbol":"CSCI","fiscalQuarterEnding":"2024/03","expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1715659200000,"reportTimeType":"post","actualEps":-4.74},{"market":"US","date":"2024-05-03","symbol":"CSCI","defaultRemindTime":1714743000000,"type":"split","dateTimestamp":1714708800000,"forFactor":4,"toFactor":1,"ratio":4},{"market":"US","date":"2024-03-27","symbol":"CSCI","fiscalQuarterEnding":"2023/12","expectedEps":-0.97,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1711512000000,"reportTimeType":"pre","actualEps":-1.16},{"market":"US","date":"2023-11-09","symbol":"CSCI","fiscalQuarterEnding":"2023/09","expectedEps":-0.61,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1699506000000,"reportTimeType":"pre","actualEps":-0.85},{"market":"US","date":"2023-08-09","symbol":"CSCI","fiscalQuarterEnding":"2023/06","expectedEps":-0.87,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1691553600000,"reportTimeType":"pre","actualEps":-0.52}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"CSCI\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"CSCI\",market:\"US\",delay:false,,,undefined,":{},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/CSCI\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"CSCI","date":"2025-04-17","current":-0.569252,"percent":0.432749,"low":-1.342161,"twenty":-0.737674,"median":-0.511293,"eighty":-0.421866,"high":-0.354008,"avg":-0.592172,"sd":0.210347,"marketCap":8714676.05},"quantilePoints":[{"date":"2024-08-09","current":-1.234741,"twenty":-1.234741,"median":-1.234741,"eighty":-1.234741,"marketCap":22285846.48},{"date":"2024-08-16","current":-1.035376,"twenty":-1.298703,"median":-1.234961,"eighty":-1.085274,"marketCap":18874905.31},{"date":"2024-08-23","current":-1.046373,"twenty":-1.235181,"median":-1.070251,"eighty":-1.046373,"marketCap":19075381.97},{"date":"2024-08-30","current":-0.646711,"twenty":-1.234741,"median":-1.046373,"eighty":-0.983923,"marketCap":11789534.32},{"date":"2024-09-06","current":-0.638249,"twenty":-1.115167,"median":-1.03327,"eighty":-0.675487,"marketCap":11635279.24},{"date":"2024-09-13","current":-0.678955,"twenty":-1.073256,"median":-0.983923,"eighty":-0.679837,"marketCap":12377345.82},{"date":"2024-09-20","current":-0.700499,"twenty":-1.052417,"median":-0.710035,"eighty":-0.681103,"marketCap":12770102.53},{"date":"2024-09-27","current":-0.870534,"twenty":-1.04669,"median":-0.70378,"eighty":-0.675123,"marketCap":15869835.94},{"date":"2024-10-04","current":-0.812319,"twenty":-1.046373,"median":-0.722807,"eighty":-0.679837,"marketCap":14808567.04},{"date":"2024-10-11","current":-0.823612,"twenty":-1.037575,"median":-0.812611,"eighty":-0.681103,"marketCap":15014456.74},{"date":"2024-10-18","current":-0.802974,"twenty":-1.032006,"median":-0.812758,"eighty":-0.683384,"marketCap":14638217.58},{"date":"2024-10-25","current":-0.738119,"twenty":-1.029451,"median":-0.812319,"eighty":-0.688462,"marketCap":13455908.14},{"date":"2024-10-31","current":-0.718905,"twenty":-1.001963,"median":-0.800465,"eighty":-0.691606,"marketCap":13105636.89},{"date":"2024-11-08","current":-0.703079,"twenty":-0.91589,"median":-0.780091,"eighty":-0.695865,"marketCap":12817134.58},{"date":"2024-11-15","current":-0.522866,"twenty":-0.856342,"median":-0.738119,"eighty":-0.687319,"marketCap":12135181.54},{"date":"2024-11-22","current":-0.39149,"twenty":-0.845719,"median":-0.732029,"eighty":-0.671292,"marketCap":9086094.43},{"date":"2024-11-29","current":-0.403443,"twenty":-0.83918,"median":-0.727131,"eighty":-0.64847,"marketCap":9363515.93},{"date":"2024-12-06","current":-0.385625,"twenty":-0.828834,"median":-0.721375,"eighty":-0.589289,"marketCap":8949957.59},{"date":"2024-12-13","current":-0.398446,"twenty":-0.825215,"median":-0.7103,"eighty":-0.441978,"marketCap":9247546.21},{"date":"2024-12-20","current":-0.368453,"twenty":-0.823612,"median":-0.703079,"eighty":-0.40351,"marketCap":8551429.49},{"date":"2024-12-27","current":-0.354008,"twenty":-0.822925,"median":-0.700499,"eighty":-0.400312,"marketCap":8216176.79},{"date":"2025-01-03","current":-0.366337,"twenty":-0.820177,"median":-0.697815,"eighty":-0.39149,"marketCap":8502327.93},{"date":"2025-01-10","current":-0.549683,"twenty":-0.819871,"median":-0.692542,"eighty":-0.395197,"marketCap":12757589.46},{"date":"2025-01-17","current":-0.453181,"twenty":-0.817713,"median":-0.686747,"eighty":-0.397982,"marketCap":10517867.39},{"date":"2025-01-24","current":-0.459403,"twenty":-0.814941,"median":-0.680711,"eighty":-0.399224,"marketCap":10662286.2},{"date":"2025-01-31","current":-0.449376,"twenty":-0.813118,"median":-0.659797,"eighty":-0.401449,"marketCap":10429572.57},{"date":"2025-02-07","current":-0.444691,"twenty":-0.812728,"median":-0.64891,"eighty":-0.401449,"marketCap":10320829.98},{"date":"2025-02-14","current":-0.444115,"twenty":-0.812576,"median":-0.634774,"eighty":-0.402647,"marketCap":10307464.39},{"date":"2025-02-21","current":-0.444619,"twenty":-0.812459,"median":-0.585859,"eighty":-0.40299,"marketCap":10319151.51},{"date":"2025-02-28","current":-0.463341,"twenty":-0.808581,"median":-0.555854,"eighty":-0.40351,"marketCap":10753682.12},{"date":"2025-03-07","current":-0.45439,"twenty":-0.80197,"median":-0.542309,"eighty":-0.404792,"marketCap":10545942.19},{"date":"2025-03-14","current":-0.539169,"twenty":-0.799986,"median":-0.531018,"eighty":-0.4069,"marketCap":12513575.96},{"date":"2025-03-21","current":-0.522896,"twenty":-0.79918,"median":-0.538944,"eighty":-0.407527,"marketCap":12135902.1},{"date":"2025-03-28","current":-0.508957,"twenty":-0.783883,"median":-0.522881,"eighty":-0.413243,"marketCap":11812377.03},{"date":"2025-04-04","current":-0.443851,"twenty":-0.753809,"median":-0.508957,"eighty":-0.422197,"marketCap":10301335.32},{"date":"2025-04-11","current":-0.587922,"twenty":-0.740942,"median":-0.507954,"eighty":-0.413243,"marketCap":9000500.81},{"date":"2025-04-17","current":-0.569252,"twenty":-0.737674,"median":-0.511293,"eighty":-0.421866,"marketCap":8714676.05}],"updateTime":1745310148215}}}